Clinical Trial Update: Oral Arsenic Trioxide for NPM1-mutated AML [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating oral arsenic trioxide for NPM1-mutated AML (NPMc+ AML).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Npm1-mutated AML
• Npmc AML

Drugs mentioned

• Oral arsenic trioxide (arsenic trioxide)

Snippet

Sponsor: The University of Hong Kong | Conditions: NPMc+ AML | Phase 2 | Status: UNKNOWN